Rheumatology prior authorization at Florida Blue
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Florida Blue rheumatology PA at a glance
Florida Blue reviews rheumatology PA submissions against its medical policy library, with rules drawn primarily from ACR (American College of Rheumatology) treatment guidelines. Florida Blue-specific context: BCBS licensee for Florida (~5M members). Owned by GuideWell. Prime Therapeutics is the PBM (BCBS-aggregated PBM serving 19 BCBS plans). Florida OIR oversight. Largest ACA Marketplace participant in FL.
Documentation packet — what to send
- Diagnosis with ICD-10-CM (RA, PsA, AS, SLE, etc.)
- Disease activity score with date
- Prior csDMARD trials: drug, dose, duration, response
- Joint count or disease-specific severity marker
- Tuberculosis screening prior to biologic
- Specialty pharmacy enrollment if required by plan
Common denial patterns to pre-empt
Patterns observed in rheumatology across payers, and where Florida Blue's book of business overlaps:
- Step therapy requiring biosimilar before reference biologic
- Step therapy requiring methotrexate / sulfasalazine / leflunomide first
- Disease activity score not documented (DAS28, CDAI, BASDAI)
- Conventional DMARDs not failed in adequate duration / dose
- Specialty pharmacy network restrictions
- Marketplace narrow-network denials (BlueCare, myBlue)
- Step therapy via Prime Therapeutics PBM
- Out-of-network reductions citing UCR
- Specialty drug prior auth
Appeal angles when Florida Blue denies
- ACR / EULAR treatment-target guideline citation
- Documented intolerance or contraindication to step-therapy alternatives
- Functional impairment (HAQ, work limitation)
- Erosive disease on imaging warranting accelerated therapy
Peer-to-peer prep
- Quote the ACR treatment guideline by year + recommendation strength
- Have the disease-activity score worksheet open
- Document the patient's functional limitation in plain terms (e.g. 'unable to dress without help')
- State explicitly which step-therapy agents were tried and why each was discontinued
Drug-specific PA criteria at Florida Blue
Deep dives on each drug's PA criteria at Florida Blue:
Frequently asked questions
What documentation does Florida Blue need for rheumatology prior authorizations?
Florida Blue's PA packet for rheumatology typically includes: Diagnosis with ICD-10-CM (RA, PsA, AS, SLE, etc.); Disease activity score with date; Prior csDMARD trials: drug, dose, duration, response; Joint count or disease-specific severity marker. ACR (American College of Rheumatology) treatment guidelines citations strengthen the submission.
What's the turnaround at Florida Blue?
Florida Blue standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which rheumatology drugs does Florida Blue most often PA-restrict?
Top targets in rheumatology: adalimumab, infliximab, rituximab, ustekinumab, secukinumab. Each follows the per-drug step therapy + documentation requirements published in Florida Blue's medical policy library.
How do I prep a peer-to-peer with Florida Blue in rheumatology?
Quote the ACR treatment guideline by year + recommendation strength Have the disease-activity score worksheet open Have the policy URL and the patient's chart open before the call.
Generate a Rheumatology PA packet
Open ApprovalHelp — generate a rheumatology PA packet tailored to Florida Blue's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com